IMV to showcase its DPX® delivery technology in two presentations at the 2022 AACR Annual Meeting

IMV to showcase its DPX® delivery technology in two presentations at the 2022 AACR Annual Meeting

  • IMV’s DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in translational and preclinical studies

  • Clinical data from the Company’s basket study in advanced metastatic bladder cancer will be presented at the “Immunotherapy Combination Strategy in Clinical Trials” mini-symposium

DARTMOUTH, Nova Scotia and CAMBRIDGE, Mass., March 09, 2022–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, announced today that the Company will showcase its DPX delivery technology in two presentations at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 8-13, 2022, in New Orleans, Louisiana.

“The data to be presented suggest that our DPX delivery platform educates an innate immune response involving NK cells in addition to the previously recognized role for T and B cells,” said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc. “This discovery supports our clinical strategy of combining our lead compound with other therapies that have a complementary mechanism of action to enhance tumor killing while maintaining a favorable safety profile.”

Translational research using both clinical samples from the DeCidE ovarian cancer trial and tissues from preclinical models will be presented, showing for the first time that natural killer (NK) cells play a distinct role in the promoting antitumor responses to the company’s leading DPX-. immunotherapeutic peptide, Maveropepimut-S.

In an oral presentation at a late-breaking session on immunotherapeutic combinations, Dr. Olivier Rixe will present safety and efficacy data from the Phase 2 IMV basket study evaluating MVP-S in combination with pembrolizumab and cyclophosphamide in patients with advanced metastatic bladder cancer.

Presentations Details

Dr. Rixe and members of the IMV team will attend the conference and both presentations will be available on the conference platform and on the IMV website under Scientific Publications & Posters section.

Presenter: Moamen Bydoun, Ph.D., Principal Investigator at IMV
Poster number: 623
Date/Time: Sunday, April 10, 2022, 1:30 p.m. – 5:00 p.m. CST

  • Safety, Preliminary Efficacy, and Pharmacodynamic (PD) Analysis of Maveroppimut-S, Low-Dose Intermittent Cyclophosphamide, and Pembrolizumab in Patients With Advanced Metastatic Bladder Cancer

Presenter: Olivier Rixe, MD, Ph.D., Quantum Santa Fe, New Mexico
Session Title: Strategies for Combining Immunotherapies in Clinical Trials
Presentation number: CT035
Session date and time: Tuesday, April 12, 2022, 2:30 p.m. – 4:30 p.m. CST

About IMV

IMV Inc. is a clinical-stage immuno-oncology company offering a portfolio of therapies based on the company’s immune education platform: DPX® Technology. Through a differentiated mechanism of action, the DPX platform provides instructions to the immune system to generate a specific, robust and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-known cancer antigen commonly overexpressed in advanced cancers. MVP-S treatment was well tolerated and demonstrated definite clinical benefit in multiple cancer indications as well as activation of a targeted and sustained survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematological and solid cancers, including diffuse large B-cell lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy based on the DPX immune delivery platform, DPX-SurMAGE. This dual-target immunotherapy combines antigenic peptides for survivin and cancer proteins MAGE-A9 to simultaneously trigger immune responses to these two distinct cancer antigens. A phase 1 clinical trial in bladder cancer was launched in early 2022. For more information, visit and join us on Twitter and LinkedIn.

IMV forward-looking statements

This press release contains forward-looking information under applicable securities laws. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use words such as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terms. Forward-looking statements are based on management’s estimates and opinions as of the date the statements are made. In the press release, these forward-looking statements include, but are not limited to, statements regarding the Company’s ability to advance its development strategy, as well as the outlook for its lead immunotherapy and other immunotherapeutic candidate pipeline. and the expected timing of the Company’s clinical trial programs and studies. However, they should not be taken as a representation that any of the plans will be realized. Actual results may differ materially from those indicated in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all approvals. regulations to begin, then continue, clinical studies. and testing and receipt of all regulatory approvals to market its products. IMV Inc. assumes no responsibility to update any forward-looking statements in this press release, except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and such risks and uncertainties include, but are not limited to, the ability to access capital, the success and generally the timely completion of trials and clinical studies and receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current Annual Information Form, as well as its audited annual consolidated financial statements which are available on SEDAR at and on EDGAR at

See the source version on


Investor Relations

Joy Bessenger, Senior Vice President, Investor Relations and Corporate Strategy
O: (902) 492.1819 ext: 2009
Email: [email protected]

Marc Jasmin, Senior Director, Investor Relations, IMV Inc.
Phone: (902) 492-1819 ext: 1042
M: (514) 617-9481 Email: [email protected]

Irina Koffler, Managing Director, LifeSci Advisors
Telephone: (646) 970-4681
M: (917) 734-7387
Email: [email protected]


Delphine Davan, Senior Director, Communications and Investor Relations, IMV Inc.
M: (514) 968 1046
Email: [email protected]

Madeline Joanis, Senior Account Manager, LifeSci Communications
M: (603) 479 5267
Email: [email protected]